Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
44.56
+0.70 (1.60%)
Jul 26, 2024, 4:30 PM EDT - Market closed
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $156.00K in the quarter ending March 31, 2024, a decrease of -83.87%. This brings the company's revenue in the last twelve months to $6.07M, up 92.76% year-over-year. In the year 2023, Celldex Therapeutics had annual revenue of $6.88M with 192.02% growth.
Revenue (ttm)
$6.07M
Revenue Growth
+92.76%
P/S Ratio
483.91
Revenue / Employee
$37,950
Employees
160
Market Cap
2.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
QuidelOrtho | 2.86B |
Integra LifeSciences Holdings | 1.53B |
PTC Therapeutics | 927.56M |
Myriad Genetics | 774.20M |
UFP Technologies | 407.33M |
Beam Therapeutics | 360.91M |
Vericel | 207.78M |
Intellia Therapeutics | 52.60M |
CLDX News
- 10 days ago - Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics to Present at Jefferies Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 - GlobeNewsWire
- 2 months ago - Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis - GlobeNewsWire
- 2 months ago - Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria - GlobeNewsWire
- 5 months ago - Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference - GlobeNewsWire
- 5 months ago - Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference - GlobeNewsWire